Sana Biotechnology (NASDAQ:SANA) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Sana Biotechnology (NASDAQ:SANA) in a report published on Friday, MarketBeat reports. The firm issued a buy rating and a $7.00 price target on the stock.

SANA has been the topic of a number of other research reports. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright raised their target price on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.25.

Sana Biotechnology Stock Up 10.6 %

SANA opened at $2.93 on Friday. Sana Biotechnology has a 52 week low of $1.52 and a 52 week high of $10.50. The firm has a 50-day simple moving average of $3.03 and a two-hundred day simple moving average of $3.25. The company has a market capitalization of $654.18 million, a PE ratio of -2.09 and a beta of 1.63.

Insider Buying and Selling at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now directly owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 31.10% of the company’s stock.

Institutional Investors Weigh In On Sana Biotechnology

Institutional investors have recently made changes to their positions in the company. Cerity Partners LLC bought a new position in Sana Biotechnology during the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC boosted its position in shares of Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after buying an additional 10,548 shares during the period. Syon Capital LLC bought a new position in shares of Sana Biotechnology during the fourth quarter valued at approximately $27,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Sana Biotechnology in the third quarter worth approximately $29,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of Sana Biotechnology during the 4th quarter worth approximately $29,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.